Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 501–600 of 1,000
Schmerge, M., Earl, S. R., & Kline, C. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000043 · Cited by 8
“Investigators, 2010; Hokusai-VTE Investigators, 2013; Schulman et al., 2009, 2014) and have proven efficacious and safe for secondary prevention of VTE (Agnelli, Buller, Cohen, Curto, Gallus, Johnson, Porcari, et al., 2013; Cohen et al., 2016; Einstein Investigators, 2010; Schulman et al., 2013).”
BackgroundDirect oral anticoagulants and travel-related venous thromboembolism
Chamnanchanunt, S., & Rojnuckarin, P. (2018) · Open Medicine · doi:10.1515/med-2018-0085 · Cited by 8
“Schulmna, 2013 (RE-MEDY)[32] 2,856, age >18 yr, acute proximal DVT or PE DAB (1,430) oral VKA (1,426) oral, INR 2-3 1.”
BackgroundInfluentialWhen and how to use direct oral anticoagulants in patients with advanced chronic liver disease?
Maria, C. D., Galante, A., Fasoli, A., & Gottardi, A. D. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.006 · Cited by 8
Ferns, S. J., & Naccarelli, G. V. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.02.006 · Cited by 8
Dabigatran for the prevention and treatment of thromboembolic disorders
Enriquez, A. A., Baranchuk, A. M., Redfearn, D., Simpson, C. S., Abdollah, H., & Michael, K. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1034692 · Cited by 10
“d) with placebo and warfarin, respectively, in patients with DVT or PE who had completed at least 3 initial months of therapy [15].”
BackgroundIrwin, J. R., Ferguson, R. A., Weilert, F., & Smith, A. (2014) · Endoscopy International Open · doi:10.1055/s-0034-1377287 · Cited by 8
Luciani, M., Albisetti, M., Biss, B., Bomgaars, L. R., Brueckmann, M., Chalmers, E. A., Gropper, S., Halton, J. M., Harper, R., Huang, F., et al. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12093 · Cited by 8
van der Pol, L. M., Mairuhu, A. T. A., Leroyer, C., Couturaud, F., Huisman, M., Klok, F. A., & Tromeur, C. (2018) · Seminars in Interventional Radiology · doi:10.1055/s-0038-1642622 · Cited by 10
Bando, T., Ueno, Y., Shimo, D., Kuroyama, T., Mikami, K., Hori, S., & Hirai, O. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105261 · Cited by 8
Keller, K., Göbel, S., ten Cate, V., Panova‐Noeva, M., Eggebrecht, L., Nagler, M., Coldewey, M., Foebel, M., Bickel, C., Lauterbach, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103281 · Cited by 9
“Anticoagulation therapy with VKA reduces the risk for recurrent VTE by 90% [7,8] and for fatal VTE by 92% [10,11].”
BackgroundMitchell, L. G., Röshammar, D., Huang, F., Albisetti, M., Brandão, L. R., Bomgaars, L. R., Chalmers, E. A., Halton, J., Luciani, M., Joseph, D., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1744542 · Cited by 8
Latest developments in anticoagulant drug discovery
Broussalis, E., Anna, W., Trinka, E., Mutzenbach, J. S., & Killer‐Oberpfalzer, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.011 · Cited by 10
Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants
Rosovsky, R. P. G., & Merli, G. J. (2017) · Techniques in vascular and interventional radiology · doi:10.1053/j.tvir.2017.07.003 · Cited by 8
New and upcoming treatments in antiphospholipid syndrome: A comprehensive review
Signorelli, F., Balbi, G. G. M., Domingues, V., & Levy, R. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.012 · Cited by 8
Secondary prevention of venous thromboembolism
Schulman, S., & Douketis, J. D. (2013) · BMJ · doi:10.1136/bmj.f5440 · Cited by 8
Self-citationHosokawa, K., & Abe, K. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.03.006 · Cited by 7
Barrios, V., & Escobar, C. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1053871 · Cited by 8
Kommentar zur 2014-ESC-Leitlinie zum Management der akuten Lungenembolie
Konstantinides, S., Bauersachs, J. K., Mayer, E., & Hambrecht, R. (2015) · Der Kardiologe · doi:10.1007/s12181-015-0008-6 · Cited by 7
Anticoagulación en enfermedad tromboembólica venosa
Milena Morales, M., Luis Arboleda, R., & Ariel Bello, E. (2019) · Revista chilena de cardiología · doi:10.4067/s0718-85602019000200122 · Cited by 7
Riva, N., & Ageno, W. (2015) · PubMed · doi:10.2450/2015.0057-15 · Cited by 9
Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301072 · Cited by 8
Respiratory Review of 2013: Pulmonary Thromboembolism
Hwang, H.-G., & Schulman, S. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.3.89 · Cited by 9
Self-citationThe role of novel anticoagulants in the management of venous thromboembolism
Skeik, N., Murphy, C. J., & Porten, B. R. (2014) · Vascular Medicine · doi:10.1177/1358863x14534309 · Cited by 7
Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos, A. C., & Turpie, A. G. G. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803462 · Cited by 7
Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson, C. M., & Finks, S. W. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.048 · Cited by 7
Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya
Obayo, A., Ngunga, M., Shah, J., Sokwala, A. P., & Barasa, A. L. (2022) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2021-060 · Cited by 7
Adverse Events of DOACs in Children
Bosch, A., & Albisetti, M. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.932085 · Cited by 7
“The low death rate aligns with the low death rate in the adult DOAC studies (9, 10).”
BackgroundLiu, Z., Tan, J., Deng, Y.-R., Hua, L., & Guo, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120414 · Cited by 7
An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism
Martins, M. D. A., Silva, T. F., & Fernandes, C. J. C. D. S. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01384-7 · Cited by 7
Anticoagulants: From chance discovery to structure-based design
Chan, N., Carlin, S., & Hirsh, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100037 · Cited by 7
Role of Novel Anticoagulants for Patients with Mechanical Heart Valves
Forsberg, P. A., & DeSancho, M. T. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0448-7 · Cited by 7
A systematic update on the state of novel anticoagulants and a primer on reversal and bridging
Knepper, J. P., Horne, D. C., Andrea, T., & Wakefield, T. W. (2013) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2013.04.006 · Cited by 7
Update on Pharmacologic Therapy for Pulmonary Embolism
Harikrishnan, P., Palaniswamy, C., & Aronow, W. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413506612 · Cited by 9
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism
Bauersachs, R. M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.05.022 · Cited by 7
“Phase III extended treatment studies of non-vitamin K antagonist oral anticoagulants for the long-term prevention of recurrent symptomatic venous thromboembolism EINSTEIN EXT [23] AMPLIFY-EXT [28] RE-SONATE [26] RE-MEDY [26] NOAC Rivaroxaban Apixaban Dabigatran Dabigatran Active comparator Placebo Placebo Placebo Warf…”
BackgroundMethodInfluentialAn update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
“The RE-SONATE [70] was a randomized, double-blind study”
MethodInfluentialThe Treatment of Venous Thromboembolism in Patients with Cancer
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_111 · Cited by 7
Li, G., Zeng, J., Zhang, J., & Thabane, L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00280 · Cited by 10
“EINSTEIN-PE (2012) (19) 4,832 DOAC 2,419 (46%) 58 4.”
Zhuang, Y., Dai, L., & Chen, M. (2021) · JRSM Open · doi:10.1177/20542704211010686 · Cited by 7
The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism
Escolar, G., Díaz‐Ricart, M., Arellano‐Rodrigo, E., & Galan, A. M. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.882897 · Cited by 7
Oral Anticoagulation in the Elderly: New Oral Anticoagulants–Innovative Solution for an Old Problem?
Barbosa, M., & Falcão, L. M. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000452 · Cited by 9
Enea, I., Roncon, L., Gulizia, M. M., Azzarito, M., Becattini, C., Bongarzoni, A., Casazza, F., Cuccia, C., D’Agostino, C., Rugolotto, M., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux026 · Cited by 7
Farinola, N., Caughey, G. E., Bell, J. S., Johns, S., Hauta‐aho, M., & Shakib, S. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617747835 · Cited by 7
Extended anticoagulation for unprovoked venous thromboembolism
Castellucci, L. A., de Wit, K., Garcia, D. A., Ortel, T. L., & Gal, G. L. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12121 · Cited by 7
Hong, K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.01970 · Cited by 7
“Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism (RESONATE; placebo-control study, n=1,353) and Twice-daily Oral Direct Thrombin Inhibitor Dabigatr…”
BackgroundUsing non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases
-, I. C. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s204377 · Cited by 7
“Three NOACs were evaluated for extended treatment of VTE in comparison with warfarin or placebo in patients already treated with anticoagulant for a specified period in separate extension clinical studies (eg, RE-MEDY and RESONATE with dabigatran, EINSTEIN-Extension with rivaroxaban, AMPLIFY-EXT with apixaban).(31,32,…”
MethodAn, J., Sun, B., Ji, Y., Zhang, Z., Zhai, Z., & Wang, C. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13167 · Cited by 8
Guided duration of anticoagulation after unprovoked venous thromboembolism using D-dimer testing
Couturaud, F. (2016) · European Respiratory Journal · doi:10.1183/13993003.00212-2016 · Cited by 7
Piazza, G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac731 · Cited by 8
Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer
Bowhay-Carnes, E. A., Haldar, A. K. S., & Madan, J. S. S. (2015) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000222 · Cited by 6
“There was no subset analysis performed for patients with active cancer [21].”
BackgroundEichinger, S., Lin, M., Shi, M., GROSSO, M. A., & Kyrle, P. A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.07.028 · Cited by 6
Pathway for the Diagnosis and Management of Pulmonary Embolism
Herzog, E., Elbaz‐Greener, G., Planer, D., Koren, T., Amir, O., Shapiro, J. M., & Kalish, Y. (2021) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000252 · Cited by 6
“as a first choice based on their excellent safety profile and their excellent extended treatment data (11-13).”
BackgroundThe multidirectional effects of thrombin and the possibility of their control in neurology
Chan, M. D., Yasamanova, A. N., Avakyan, G. G., Никонова, А. А., & Kamchatnov, P. R. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412403242 · Cited by 6
Hu, Z., Persaud, Y., & Ahuja, S. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104347 · Cited by 6
Bazell, C. M., Alston, M., Ganti, L., Chang, R. C., Wilsey, H. A., Leary, S., Fopalan, W., & Baugh, C. W. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03287-4 · Cited by 6
“Although DOACs are effective and have better safety profiles than VKAs, their use is still associated with an increased risk of severe bleeding [24, 25].”
New indications for dabigatran: A suggestion from a drug use evaluation study
Mousavi, S., Ashrafi, F., & Rezaie, N. (2017) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_17_54 · Cited by 7
“25) for prevention of recurrent VTE; however, compared to placebo, dabigatran increased the risk of major bleeding.[7]”
BackgroundAspirin in secondary prevention of recurrent venous thromboembolism
Boonyawat, K., & Crowther, M. A. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1196-4 · Cited by 6
Granziera, S., Hasan, A., & Cohen, A. T. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615600791 · Cited by 7
“The principal safety outcome varied between studies and was defined as major bleeding (according to the International Society on Thrombosis and Haemostasis definition) in AMPLIFY8 and clinically relevant bleeding (composite of major and nonmajor clinically relevant bleeding) in EINSTEIN DVT, EINSTEIN PE,10,11 and Hoku…”
BackgroundResultInfluentialSafety of non-vitamin K antagonist oral anticoagulants - coronary risks
Caldeira, D., Ferreira, J. J., Pinto, F. J., & Costa, J. N. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164689 · Cited by 6
“Another dabigatran trial that also generated some coronary concerns was the REMEDY trial.(13) This study compared dabigatran with VKA in patients with VTE (which excluded from the main analyses of this review).”
BackgroundResultPatel, R. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s100299 · Cited by 7
“Dabigatran significantly reduced the risk of recurrent VTE (RRR 92%) compared with placebo, but it was also associated with a significant increase in major and clinically relevant bleeding (principal safety end point).(23) Acetylsalicylic acid (ASA) has also been investigated for long-term secondary prevention of recu…”
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Modern position of anticoagulants in acute pulmonary embolism: achievements, limitations, prospects
Terekhovskaya, Y. V., Okorokov, V. G., & Николаевна, Н. Н. (2019) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj201927193-106 · Cited by 7
“dabigatran which showed efficacy and safety comparable with those of warfarin [31-33].”
BackgroundFolkerts, K., Broughton, J., Sheikh, U., & Mckaig, S. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1658589 · Cited by 8
Romiti, G. F., Corica, B., & Proietti, M. (2020) · Future Cardiology · doi:10.2217/fca-2020-0084 · Cited by 6
Anticoagulants: dose control methods and inhibitors
Bitsadze, V. O., Викторовна, С. Е., Khizroeva, J. K., Tretyakova, M. V., Tsibizova, V. I., Gashimova, N. R., Nakaidze, I. A., Elalamy, I., Gris, J., & Makatsariya, A. D. (2022) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2022.293 · Cited by 7
Rho, S., Wang, C., Dehkordi, S. H. H., Sears, J. J., & Hu, Z. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100283 · Cited by 6
“Studies have shown that novel oral anticoagulants (NOACs) are noninferior to warfarin and heparin for treatment of venous thromboembolism [28 – 30].”
BackgroundTscharre, M., Steiner, D., Mutschlechner, D., Ay, C., & Gremmel, T. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102332 · Cited by 6
Laganà, A., Assanto, G. M., Masucci, C., Passucci, M., Donzelli, L., Serrao, A., Baldacci, E., Santoro, C., & Chistolini, A. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.020 · Cited by 6
The place of new oral anticoagulants in travel medicine
Ringwald, J., Grauer, M., Eckstein, R., & Jelínek, T. (2013) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2013.11.005 · Cited by 8
The Current and Future Role of the Novel Oral Anticoagulants—Indications Beyond Atrial Fibrillation
Lee, A., & Rajaratnam, R. (2013) · Heart Lung and Circulation · doi:10.1016/j.hlc.2013.09.007 · Cited by 6
“The RE-MEDY study [21] was a randomised, double-blind, non-inferiority trial testing extended therapy with dabigatran versus warfarin in 2866 patients with VTE whom had already received three to 12 months of anticoagulation with warfarin or dabigatran as part of the RE-COVER trials.”
MethodCurrent Management of Pulmonary Thromboembolism
Kim, Y. (2013) · Korean Journal of Medicine · doi:10.3904/kjm.2013.84.5.659 · Cited by 6
“재발의 고위험군을 대상으로 급성기 치료 후 6개월 이상 연장치료(extended therapy)를 시행하여 그 치료 효과 및 안전 성을 보고하였다[23,25,26].”
Lenchus, J. D., Biehl, M., Cabrera, J. L., de Moraes, A. G., & Dezfulian, C. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066616648265 · Cited by 6
Update on Anticoagulation: What the Interventional Radiologist Needs to Know
Kamath, S. D., & McMahon, B. J. (2016) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1582124 · Cited by 6
Nuevos anticoagulantes orales: actualización
Berkovits, A., & Mezzano, D. (2017) · Revista chilena de cardiología · doi:10.4067/s0718-85602017000300254 · Cited by 6
Siniscalchi, C. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.026 · Cited by 6
Lin, Y., Lin, M., Wu, V. C., Chen, Y., Chang, J.-J., Chu, P., Lip, G. Y. H., & Chen, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.775564 · Cited by 6
Homozygous factor V leiden mutation: Rare etiology of pulmonary embolism
Marraki, Z. E., Bouzhir, A., eddhima, Z., el bouanani, A.-E., Mouine, N., & Benyass, A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104569 · Cited by 6
Restarting oral anticoagulants after intracerebral hemorrhage: pros
Ntaios, G. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1160-x · Cited by 6
“extended treatment of VTE [15–19].”
Verlängerte Sekundärprophylaxe nach venöser Thromboembolie
Bauersachs, R. M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-113679 · Cited by 8
“Im Vergleich zu VKA war Dabigatran nach abgeschlossener Erhaltungstherapie nicht unterlegen bezüglich der Wirksamkeit, bei gleichzeitiger signifikanter Reduktion von Majorblutungen [10].”
BackgroundInfluentialAmado, V. M., Fernandes, C. J. C. D. S., Salibe-Filho, W., Gazzana, M. B., Rocha, A. T., Yoo, H. H. B., Bernardo, W. M., & Tanni, S. É. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20240314 · Cited by 5
“(16,36) This risk must be weighed against the potential hemorrhagic complications associated with anticoagulant use.”
InfluentialBozkurt, A. K., Akay, H. T., Çalkavur, T., Şırlak, M., Balkanay, O. O., Uğuz, E., Doğancı, S., Polat, A., Bayrak, S., Bozok, Ş., et al. (2021) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2021.22121 · Cited by 6
“However, researches are ongoing due to the high risk of rethrombosis.[32-37] In comparative studies with DOACs, 2.”
BackgroundMithoowani, S., Bungard, T. J., Castellucci, L. A., Crowther, M., de Wit, K., Dowlatshahi, D., Forbes, N., Lin, K. Y., & Siegal, D. M. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2464-2887 · Cited by 8
The New Era of Anticoagulation
Skeik, N., Rumery, K. K., & Rodriguez, G. T. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.07.013 · Cited by 8
Akwaa, F., & Spyropoulos, A. C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.951425 · Cited by 5
Duration of Anticoagulation for Venous Thromboembolic Events
Smilowitz, N. R., Mega, J. L., & Berger, J. S. (2014) · Circulation · doi:10.1161/circulationaha.114.010456 · Cited by 6
ten Cate‐Hoek, A. J., Weitz, J. I., Gailani, D., Meijer, K., Philippou, H., Bouman, A. C., Cheung, Y. W., van Mens, T. E., Govers‐Riemslag, J. W. P., Vries, M. J. A., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.036 · Cited by 5
“When compared with warfarin for extended VTE treatment, dabigatran had similar efficacy but was associated with a 50% reduction in the rate of major bleeding [27].”
BackgroundWong, W. H., Yip, C. Y. C., Sum, C. L. L., Tan, C. W., Lee, L. H., Yap, E. S., Kuperan, P., Ting, W. C., & Ng, H. J. (2016) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v45n3p98 · Cited by 5
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism
Imberti, D., Pomero, F., Benedetti, R., & Fenoglio, L. M. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1521-8 · Cited by 6
Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report
Choe, H. J., Suh, K. J., Lee, J. Y., Kim, M., Kim, M. J., Park, S. S., Kim, J., Kim, S. H., Kim, J. W., Lee, J., et al. (2019) · Medicine · doi:10.1097/md.0000000000016318 · Cited by 5
“Furthermore, a sub-group analysis by Schulman et al demonstrated that dabigatran was non-inferior to warfarin in patients with inherited thrombophilia in recurrent VTE or VTE-related deaths.([20]) In our case, there was no residual VTE in the repeated CT imaging 6 months after rivaroxaban treatment.”
MethodPLEIOTROPIC EFFECTS OF ORAL ANTICOAGULANTS
Galyautdinov, G. S., Feiskhanova, L. I., & Abdullaev, S. P. (2019) · Гематология и трансфузиология · doi:10.35754/0234-5730-2019-64-1-90-98 · Cited by 5
Quelle est la durée du traitement anticoagulant pour une EP/TVP proximale ?
Couturaud, F., Girard, P., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.022 · Cited by 5
Li, D., Liu, Y., Song, Y. H., & Wen, A. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2026002 · Cited by 5
“RE-MEDY and RE-SONATE studies have assessed effects of dabigatran versus warfarin or placebo during the extended anticoagulation of VTE [51], we did not include these RCTs because either the publication [51] or the registered website [52] reported the actual percentage of unprovoked patients.”
BackgroundWenger, N., Sebastian, T., Beer, J. H., Mazzolai, L., Aujesky, D., Hayoz, D., Engelberger, R. P., Korte, W. C., Voci, D., Kucher, N., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.10.006 · Cited by 5
“Clinical trials of extended DOAC therapy have shown no significant difference in recurrence or efficacy between DVT-only and PE patients [30 – 32].”
BackgroundWilson, M. R., & Tait, R. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00023-2 · Cited by 5
Conventional and New Oral Anticoagulants in the Treatment of Chest Disease and its Complications
Gallego, P., Roldán, V., & Lip, G. Y. H. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201301-0141pp · Cited by 5
Blood thinners and gastrointestinal endoscopy
Ahmed∥, M. (2016) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v8.i17.584 · Cited by 5
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?
Howard, L. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1452614 · Cited by 5
“Patients who had been included in the registration studies and in whom a decision about continued treatment with anticoagulation therapy was unclear, ongoing treatment with NOAC was associated with a large reduction in the number of recurrent venous thromboembolic events compared with placebo [19,22,26].”
BackgroundLobastov, K. V. (2019) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia201905194 · Cited by 5
Direct-acting oral anticoagulants in antiphospholipid syndrome
Reshetnyak, T. M., & Nurbaeva, K. S. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2020-708-715 · Cited by 5
Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents
Stevens, H., McFadyen, J. D., & Chan, N. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1723953 · Cited by 5
Ma, T., Liu, C., Jiang, T., Qin, H., Wu, R., & Zhou, P. (2021) · Medicine · doi:10.1097/md.0000000000024522 · Cited by 5
“Author Study Year Clinical condition Intervention and dose Age (yr) ICH (n) Mortality (n) Patients (n) Double blind Followup Sato H JAFST[22] 2006 Atrial fibrillation Aspirin 150–200mg per day 65.5 4 10 426 No 2.1 yr Placebo 64.8 2 9 445 Hori M J- ROCKET AF[23] 2011 Atrial fibrillation Rivaroxaban 15mg once daily 71.0…”
BackgroundInfluential
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.